CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 2,172 target
Drug / intervention
Docetaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03926091
NCT03926091Phase 3Unknown
CompareCT.gov

A Prospective, Multisite, Randomized, Open-label Phase III Clinical Trial (CLOVER Study)Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Fudan University·interventional·Posted Apr 24, 2019·Updated Nov 14, 2023

In Brief

A Phase 3 clinical trial evaluating Docetaxel and Cyclophosphamide for Breast Cancer. Targeting 2,172 participants across 14 sites.

Detailed Summary

This is a prospective, multisite, randomized, open-label Phase III clinical trial (CLOVER study) comparing 4 cycles with 6 cycles of TC (docetaxel+cyclophosphamide) adjuvant chemotherapy for 1-3 positive lymph node, ER+/HER2- early breast cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--

Timeline

Phase 3UnknownOverdue
2020202120222023202420252026
First PostedApr 24, 2019
Enrollment StartApr 1, 2019
Primary CompletionNov 1, 2024
Study CompletionNov 1, 2025
TodayJul 1, 2026
Enrollment to primary: 5.6 yearsPosted 7.2 years ago

Interventions

Docetaxeldrug

Docetaxel chemotherapy (injection)

Cyclophosphamidedrug

Cyclophosphamide chemotherapy (injection)